Redeye: Moberg Pharma - Plenty of value

Report this content

The OTC business continues to deliver solid performance, in-line with our expectations. Due to divestments, revenues are expected to decline this year. Following the 4Q17 report, we have made only modest changes to our estimates (adjusted for the divestment of Balmex).

Read more in the Research Update by Klas Palin:

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.